Skip to main content
Actavis ramped up drug price by 12,000 per cent

GRASPING pharmaceutical company Actavis UK was slammed yesterday for outrageously ramping up the price of a life-saving drug by more than 12,000 per cent.

The Competition and Markets Authority (CMA) said that Actavis, formerly known as Auden Mckenzie, increased the price of 10mg hydrocortisone tablets — used to treat a range of conditions including allergic disorders, psoriasis and arthritis — from 70p in April 2008 to a shocking £88 per pack by March 2016.

The firm has also been condemned for increasing the price of 20mg hydrocortisone tablets by nearly 9,500 per cent compared with the previous branded price — from £1.07 to £102.74 per pack. The cynical price rises sent the amount the NHS spent on hydrocortisone tablets from approximately £522,000 to £70 million a year by 2015.

The 95th Anniversary Appeal
Support the Morning Star
You have reached the free limit.
Subscribe to continue reading.
More from this author
Britain / 24 March 2017
24 March 2017
Anti-racist and faith groups lead vigil for terrorist attack victims
Britain / 24 March 2017
24 March 2017
Britain / 11 March 2017
11 March 2017
Britain / 11 March 2017
11 March 2017
Similar stories
US President Donald Trump meeting Prime Minister Keir Starme
Editorial: / 2 April 2025
2 April 2025
Billionaires: Facebook CEO Mark Zuckerberg, Amazon CEO Jeff
Features / 25 January 2025
25 January 2025
The government needs to raise its game when it comes to the tech giants who behave like the robber barons of old, argues NICK MATTHEWS
LINING THEIR POCKETS: Gilead Sciences HQ in Foster City, Cal
Science and Society / 18 December 2024
18 December 2024
Despite miraculous trial results showing new treatment could halt transmission, corporate greed and patent laws condemn millions to preventable infection and death, write ROX MIDDLETON, LIAM SHAW and MIRIAM GAUNTLETT
An electron micrograph of HIV-1 virus particles (colourized
Features / 13 September 2024
13 September 2024
ALAN ROSSI SILVA argues that Gilead’s HIV prevention drug, while promising, highlights systemic failures in the pharmaceutical industry, showing the need to shift towards state-owned drug development and production